- Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025
- Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025
- Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34%
- Reiterate full year net product revenue guidance of $135 million to $150 million, representing full year total roxadustat net sales in China1 between $330 million to $350 million
- Meaningful progress on U.S. cost reduction plan
- Expected to be substantially complete by year-end 2024
- Cash, cash equivalents and accounts receivable balance of $160.0 million
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. ( FGEN) today reported financial results for the third quarter 2024 and provided an update on the company’s recent developments.
“This past quarter we transformed into a lean and more focused organization, resulting in significant cost savings that will extend into the future. Moreover, roxadustat continued its impressive performance, generating $96.6 million in net sales in China during the quarter,” said Thane Wettig, Chief Executive Officer, FibroGen. “Having implemented our cost reduction plan, we are well positioned to advance FG-3246, with topline results from the Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide at the University of California San Francisco (UCSF) on track for the first half of 2025, and the anticipated start of our Phase 2 monotherapy trial in the first quarter of 2025. We continue to be optimistic about our future prospects.”
Recent Developments and Key Events of Third Quarter 2024:
- Meaningful progress on U.S. cost reduction plan.
- Expected to be substantially complete by year-end 2024
- Reported topline results from the pamrevlumab arm of PanCAN Precision Promise Phase 2/3 adaptive platform trial for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), in which the trial did not meet the primary endpoint.
- Reported topline results from the LAPIS Phase 3 study of pamrevlumab in patients with locally advanced, unresectable pancreatic cancer (LAPC), in which the trial did not meet the primary endpoint.
Upcoming Milestones:
Roxadustat
- Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in early 2025. If approved, FibroGen will receive a $10 million milestone payment from AstraZeneca.
FG-3246 and FG-3180 (PET Imaging Agent)
- Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 1H 2025.
- Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in 1Q 2025. This trial will include a sub-study of FG-3180 to enable assessment of CD46 expression and response to FG-3246.
China:
- Third quarter FibroGen net product revenue under U.S. GAAP from the sale of roxadustat in China was $46.2 million compared to $29.4 million in the third quarter of 2023, an increase of 57% year over year.
- Third quarter total roxadustat net sales in China1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca (JDE) was $96.6 million, compared to $77.1 million in the third quarter of 2023, an increase of 25% year over year, driven by a 34% increase in volume.
- Roxadustat continues to be the number one brand based on value share in the anemia of CKD market in China.
- For 2024, FibroGen’s expected full year net product revenue under U.S. GAAP reiterated to a range between $135 million to $150 million, representing expected full year roxadustat net sales in China1 by FibroGen and the JDE of $330 million to $350 million.
Financial:
- Total revenue for the third quarter of 2024 was $46.3 million, as compared to $40.1 million for the third quarter of 2023, an increase of 15% year over year.
- Net loss for the third quarter of 2024 was $17.1 million, or $0.17 net loss per basic and diluted share, compared to a net loss of $63.6 million, or $0.65 net loss per basic and diluted share one year ago.
- At September 30, 2024, FibroGen reported $160.0 million in cash, cash equivalents and accounts receivable.
- Assuming additional repatriation of cash from our China operations, we expect our cash, cash equivalents and accounts receivable to be sufficient to fund our operating plans into 2026.
Conference Call and Webcast Details
FibroGen management will host a conference call and webcast today, Tuesday, November 12, 2024, at 5:00 PM Eastern Time to discuss financial results and provide a business update. Interested parties may access the conference call by dialing 1-877-300-8521 (in the U.S.) or 1-412-317-6026 (outside the U.S.). The call will be available via webcast by clicking here or on the “Events and Presentation” page on the FibroGen website.
About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted by the China Health Authority.
Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa. AstraZeneca and FibroGen continue to collaborate on the development and commercialization of roxadustat in China.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET imaging agent, FG-3180. In addition, FibroGen’s research and development portfolio includes two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of FibroGen products and product candidates, statements under the caption “Upcoming Milestones”, statements regarding the potential for cash, cash equivalents and accounts receivable to fund FibroGen’s operating plans into 2026, and statements about FibroGen’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
1 Total roxadustat net sales in China includes sales made by the distribution entity as well as FibroGen China’s direct sales, each to its own distributors. The distribution entity jointly owned by AstraZeneca and FibroGen is not consolidated into FibroGen’s financial statements.
Condensed Consolidated Balance Sheets
(In thousands)
| September 30, 2024 | December 31, 2023 | |||||||
| (Unaudited) | (1) | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 131,003 | $ | 113,688 | ||||
| Short-term investments | — | 121,898 | ||||||
| Accounts receivable, net | 29,030 | 12,553 | ||||||
| Inventory | 23,937 | 41,565 | ||||||
| Prepaid expenses and other current assets | 60,559 | 41,855 | ||||||
| Total current assets | 244,529 | 331,559 | ||||||
| Restricted time deposits | 1,658 | 1,658 | ||||||
| Property and equipment, net | 7,603 | 13,126 | ||||||
| Equity method investment in unconsolidated variable interest entity | 5,806 | 5,290 | ||||||
| Operating lease right-of-use assets | 2,093 | 68,093 | ||||||
| Other assets | 2,732 | 3,803 | ||||||
| Total assets | $ | 264,421 | $ | 423,529 | ||||
| Liabilities, stockholders’ equity and non-controlling interests | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 9,238 | $ | 17,960 | ||||
| Accrued and other liabilities | 151,141 | 172,891 | ||||||
| Deferred revenue | 28,858 | 12,740 | ||||||
| Operating lease liabilities, current | 1,293 | 14,077 | ||||||
| Total current liabilities | 190,530 | 217,668 | ||||||
| Product development obligations | 18,199 | 17,763 | ||||||
| Deferred revenue, net of current | 126,219 | 157,555 | ||||||
| Operating lease liabilities, non-current | 707 | 66,537 | ||||||
| Senior secured term loan facilities, non-current | 72,779 | 71,934 | ||||||
| Liability related to sale of future revenues, non-current | 56,850 | 51,413 | ||||||
| Other long-term liabilities | 837 | 2,858 | ||||||
| Total liabilities | 466,121 | 585,728 | ||||||
| Redeemable non-controlling interests | 21,480 | 21,480 | ||||||
| Total stockholders’ deficit attributable to FibroGen | (243,667 | ) | (204,166 | ) | ||||
| Nonredeemable non-controlling interests | 20,487 | 20,487 | ||||||
| Total deficit | (223,180 | ) | (183,679 | ) | ||||
| Total liabilities, redeemable non-controlling interests and deficit | $ | 264,421 | $ | 423,529 | ||||
(1)The condensed consolidated balance sheet amounts at December 31, 2023 are derived from audited financial statements.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| (Unaudited) | |||||||||||||||
| Revenue: | |||||||||||||||
| License revenue | $ | — | $ | 2,649 | $ | — | $ | 9,649 | |||||||
| Development and other revenue | 385 | 6,775 | 1,532 | 15,825 | |||||||||||
| Product revenue, net | 46,210 | 29,390 | 126,391 | 77,439 | |||||||||||
| Drug product revenue, net | (262 | ) | 1,320 | 24,954 | 17,701 | ||||||||||
| Total revenue | 46,333 | 40,134 | 152,877 | 120,614 | |||||||||||
| Operating costs and expenses: | |||||||||||||||
| Cost of goods sold | 5,295 | 4,243 | 36,227 | 13,441 | |||||||||||
| Research and development | 21,708 | 61,194 | 94,206 | 231,158 | |||||||||||
| Selling, general and administrative | 17,554 | 25,573 | 62,650 | 91,029 | |||||||||||
| Restructuring charge | 18,554 | 12,606 | 18,554 | 12,606 | |||||||||||
| Total operating costs and expenses | 63,111 | 103,616 | 211,637 | 348,234 | |||||||||||
| Loss from operations | (16,778 | ) | (63,482 | ) | (58,760 | ) | (227,620 | ) | |||||||
| Interest and other, net: | |||||||||||||||
| Interest expense | (4,994 | ) | (5,022 | ) | (14,774 | ) | (10,464 | ) | |||||||
| Interest income and other income (expenses), net | 3,802 | 4,296 | 5,092 | 7,984 | |||||||||||
| Total interest and other, net | (1,192 | ) | (726 | ) | (9,682 | ) | (2,480 | ) | |||||||
| Loss before income taxes | (17,970 | ) | (64,208 | ) | (68,442 | ) | (230,100 | ) | |||||||
| Benefit from income taxes | 12 | 84 | (217 | ) | (77 | ) | |||||||||
| Investment income in unconsolidated variable interest entity | 898 | 677 | 2,664 | 2,023 | |||||||||||
| Net loss | $ | (17,084 | ) | $ | (63,615 | ) | $ | (65,561 | ) | $ | (228,000 | ) | |||
| Net loss per share - basic and diluted | $ | (0.17 | ) | $ | (0.65 | ) | $ | (0.66 | ) | $ | (2.35 | ) | |||
| Weighted average number of common shares used to calculate net loss per share - basic and diluted | 100,515 | 98,245 | 99,780 | 96,901 | |||||||||||
For Investor Inquiries:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
[email protected]
